Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC

Clinical trial NCT07596290 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07596290
Sponsor: Beijing Friendship Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Locally Advanced Rectal Adenocarcinoma Neoadjuvant Chemoradiation Neoadjuvant Immunotherapy

Start date: 2026-07-15
Primary completion: 2028-12-31
Enrollment: 342

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.